Aug 28 2009
IntraLinks®, the leading provider of critical information exchange solutions, today announced that Fast Forward™ has selected IntraLinks to help streamline the collection, distribution and tracking of information to support their funding of multiple biotechnology and pharmaceutical companies working on new Multiple Sclerosis (MS) treatments.
"More than two million people around the world live with MS, a chronic and often debilitating disease. A cure has not yet been discovered. We believe using IntraLinks facilitates our evaluation and management of the complex data related to prospective drugs in the development pipeline. This increases our ability to make funding decisions that will expedite new treatments to the people who need them," said Maya Merrell, business manager for Fast Forward.
"IntraLinks simplifies the exchange of information between everyone involved in our due diligence and funding process -- from board members to scientific and business advisors and other external constituents. It streamlines the whole process -- crucial for the small staff at Fast Forward and its work teams based in different locations," Merrell adds.
"Often times, companies involved in research and technology development have difficulty securing funds to move scientific ideas from discovery into preclinical development," said Allison Shurell, vice president of product marketing for IntraLinks. "We're helping Fast Forward close the funding gap which had previously slowed the drug development process for MS."
Fast Forward uses 16 active IntraLinks Exchanges™ to manage global funding opportunities.
Medical and behavioral interventions can reduce fatigue in people with multiple sclerosis